NSIS B Stock Overview

Produces and sells produces various industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. More details

NSIS B fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 7.2% below our estimate of its fair value

Earnings are forecast to grow 26.94% per year

Risk Analysis

Large one-off items impacting financial results

Profit margins (8%) are lower than last year (16.9%)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Novonesis A/S Competitors

DSM-Firmenich

ENXTAM:DSFIR

€24.8b

Asian Paints

NSEI:ASIANPAINT

₹2.2t

Sika

SWX:SIKA

CHF 33.1b

Wanhua Chemical Group

SHSE:600309

CN¥174.1b

Price History & Performance

Summary of share price highs, lows and changes for Novonesis
Historical stock prices
Current Share Price	DKK 444.30
52 Week High	DKK 485.90
52 Week Low	DKK 368.50
Beta	0.55
1 Month Change	14.07%
3 Month Change	9.43%
1 Year Change	6.19%
3 Year Change	3.88%
5 Year Change	27.67%
Change since IPO	1,271.30%

Recent updates

Shareholder Returns

	NSIS B	DK Chemicals	DK Market
7D	3.3%	0.6%	-1.4%
1Y	6.2%	-8.8%	-33.2%

Return vs Industry: NSIS B exceeded the Danish Chemicals industry which returned -9.4% over the past year.

Return vs Market: NSIS B exceeded the Danish Market which returned -32% over the past year.

Price Volatility

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	4.6%
Chemicals Industry Average Movement	5.6%
Market Average Movement	5.8%
10% most volatile stocks in DK Market	9.8%
10% least volatile stocks in DK Market	3.7%

Stable Share Price: NSIS B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: NSIS B's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	10,582	Ester Baiget	www.novonesis.com

Novonesis A/S produces and sells produces various industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and early lie nutrition. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novonesis A/S Fundamentals Summary

How do Novonesis's earnings and revenue compare to its market cap?
NSIS B fundamental statistics
Market cap	DKK 207.02b
Earnings (TTM)	DKK 2.28b
Revenue (TTM)	DKK 28.60b

90.7x

P/E Ratio

7.2x

P/S Ratio

Is NSIS B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NSIS B income statement (TTM)
Revenue	€3.83b
Cost of Revenue	€1.84b
Gross Profit	€1.99b
Other Expenses	€1.69b
Earnings	€305.80m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 21, 2025

Earnings per share (EPS)	0.66
Gross Margin	52.00%
Net Profit Margin	7.98%
Debt/Equity Ratio	16.1%

How did NSIS B perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

75%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/08 00:56
End of Day Share Price	2025/05/08 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novonesis A/S is covered by 38 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Vitfell-Rasmussen	ABG Sundal Collier
Carla Bänziger	Bank Vontobel AG
Sebastian Satz	Barclays

NSIS B Stock Overview

Rewards

Risk Analysis

Novonesis A/S Competitors

ENXTAM:DSFIR

€24.8b

NSEI:ASIANPAINT

₹2.2t

SWX:SIKA

CHF 33.1b

SHSE:600309

CN¥174.1b

Price History & Performance

Recent News & Updates

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Less than half of directors are independent

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Now 24% undervalued after recent price drop

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Now 20% undervalued after recent price drop

Recent updates

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Less than half of directors are independent

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Now 24% undervalued after recent price drop

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Now 20% undervalued after recent price drop

New minor risk - Dividend sustainability

Novonesis A/S Announces Board Changes

Full year 2024 earnings: EPS misses analyst expectations

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Shareholder Returns

Price Volatility